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Clinical and demographic factors associated
with change and maintenance of disease
severity in a large registry of patients with
rheumatoid arthritis
George W. Reed1,4*, David H. Collier2, Andrew S. Koenig3, Katherine C. Saunders4, Dimitrios A. Pappas4,5,
Heather J. Litman4, Joel M. Kremer4,6 and Sameer Kotak3
Abstract
Background: We examined models to predict disease activity transitions from moderate to low or severe and
associated factors in patients with rheumatoid arthritis (RA).
Methods: Data from RA patients enrolled in the Corrona registry (October 2001 to August 2014) were analyzed.
Clinical Disease Activity Index (CDAI) definitions were used for low (≤10), moderate (>10 and ≤22), and severe (>22)
disease activity states. A Markov model for repeated measures allowing for covariate dependence was used to model
transitions between three (low, moderate, severe) states and estimate population transition probabilities. Mean sojourn
times were calculated to compare length of time in particular states. Logistic regression models were used to examine
impacts of covariates (time between visits, chronological year, disease duration, age) on disease states.
Results: Data from 29,853 patients (251,375 visits) and a sub-cohort of 9812 patients (46,534 visits) with regular visits
(every 3–9 months) were analyzed. The probability of moving from moderate to low or severe disease by next
visit was 47% and 18%, respectively. Patients stayed in moderate disease for mean 4.25 months (95% confidence interval:
4.18–4.32). Transition probabilities showed 20% of patients with low disease activity moved to moderate or severe disease
within 6 months; >35% of patients with moderate disease remained in moderate disease after 6 months. Results were
similar for the regular-visit sub-cohort. Significant interactions with prior disease state were seen with chronological
year and disease duration.
Conclusion: A substantial proportion of patients remain in moderate disease, emphasizing the need for treat-to-target
strategies for RA patients.
Keywords: Rheumatoid arthritis, Disease activity, Prediction, Markov model, Clinical Disease Activity Index
Background
Rheumatoid arthritis (RA) is a chronic, systemic inflamma-
tory disease, which can lead to progressive joint destruction
and accumulating disability from autoimmune processes
that target the synovium [1]. Several effective and safe
medications can decrease the level of inflammation and
achieve a low disease activity state or even remission [2].
Treat-to-target principles emphasize the need for achieve-
ment of remission or low disease activity [3]. However,
reaching a state of continuous and stable remission or low
disease activity is not observed in all patients despite
aggressive therapy [4–7], and a number of studies have
shown that moderate or high disease activity is not uncom-
mon in treated patients [8–12]. RA disease activity in
treated patients frequently fluctuates over time. Continuous
surveillance by the treating physician is therefore needed to
maintain disease activity at low levels and diminish the
probability of joint damage and associated disability.
Medications may fail to control the disease activity for long
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periods of time because of development of resistance, the
autoimmune process maintaining the RA-related inflam-
mation may become more active, and the disease activity
may flare.
The current therapy guidelines provide a therapy algo-
rithm, which recommends all patients should be treated
with conventional synthetic disease-modifying antirheu-
matic drugs (csDMARDs) as first-line therapy, or if they fail
to achieve low disease activity or remission with a tumor
necrosis factor inhibitor (TNFi). If there is primary or
secondary treatment failure and the patient returns to a
state of moderate disease activity, a different TNFi can be
tried, followed by switch to a non-TNFi biologic DMARD
(bDMARD) after failure of a second TNFi [3]. However,
this model of therapy does not take into account character-
istics that may affect the probability of a patient to return
to low disease activity or remission regardless of therapy. It
is possible that the previous history of disease activity
fluctuation, coupled with other patient and disease charac-
teristics, may be able to predict the future “behavior” of the
disease and thus decisions about the aggressiveness of ther-
apy could be tailored according to these probabilities.
For patients with moderate disease activity, the evolution
of disease activity over time is particularly difficult to pre-
dict currently. Understanding the patterns of fluctuation as
patients transition out of moderate disease activity provides
an assessment of the unmet needs in the RA patient popu-
lation regardless of treatment or duration of disease.
The most common modeling techniques that have
been used to predict evolution of disease activity in RA
include decision trees, Markov models, individual sam-
pling methods, and discrete event simulation [13]. These
have mainly been applied to perform cost effectiveness and
cost utility analyses using real or simulated populations
[13–16]. Few studies have used the models to examine
clinical trends in RA development and factors associated
with these transitions. In the current study we examined
the feasibility of using Markov models and clinical registry
data to estimate transition probabilities and the impact of
covariates on these transitions. We focused on the group of
patients with moderate disease activity and compared mean
times that these patients remained in their current disease
state to patients in other disease states. We used the
Corrona registry database as the clinical patient population
to provide a proof of principle that these models can poten-
tially be used to evaluate clinically relevant associations
with disease state transitions.
Methods
Patients
Patients evaluated in the current analyses were enrolled
in the Corrona registry. The Corrona registry has been
described in detail elsewhere [17]. Briefly, the Corrona
registry comprises a prospective US observational cohort
of patients with arthritis who are enrolled by participat-
ing rheumatologists [17, 18]. The Corrona registry was
founded in 2001. The Corrona Rheumatology Practice
Network is composed of more than 100 private and
academic practices across 42 states within the USA, with
more than 350 rheumatologists contributing data. All
geographic regions in the continental USA are repre-
sented and there are no restrictions on age, disease ac-
tivity, or disease duration or other restrictions to patient
participation in the registry.
Data are collected from both patients and their treating
rheumatologists, who gather information on disease
duration, prognosis, disease severity and activity, medical
comorbidities, use of medications including csDMARDs
and bDMARDs, and adverse events. Follow-up assess-
ments are requested at least as often as every 6 months
and completed during routine clinical encounters. At each
Corrona registry visit patients and physicians record data
on disease severity and activity, RA and other medications,
adverse events, quality of life, selected laboratory and
imaging results, and sociodemographic information. Visits
have occurred at a median interval of 4.4 months.
The study population used for analysis of the impact of
intervals between visits consisted of 29,853 RA patients
with 251,375 visits with Clinical Disease Activity Index
(CDAI) components measured at all visits in Corrona
from October 2001 to August 2014. Only 1.2% of patients
(n = 371) were dropped because of a visit with no CDAI
assessment. A subset of patients with all visit intervals be-
tween 3 and 9 months (regular-visit sub-cohort) was used
for covariate analyses beyond visit length, and included
9812 RA patients with 46,534 visits.
Measurement of disease activity
Disease activity was measured using the CDAI, an estab-
lished composite measure of disease activity [19]. CDAI
is calculated based on the number of swollen and tender
joints, the patient’s self assessment of overall RA disease
activity (scale of 1–10), and the physician’s (or evalua-
tor’s) assessment of overall RA disease activity (scale of
1–10 where 10 is maximal activity). CDAI uses the 28-
joint scale to evaluate the number of swollen and tender
joints - thus ankles and feet are excluded. Inflammation
markers are not included in CDAI calculation. CDAI
cutoffs have been established to define different disease
activity states; remission is defined by a CDAI ≤2.8, low
disease activity is defined by a CDAI >2.8 and ≤10, mod-
erate disease activity is defined by a CDAI >10 and ≤22
and high disease activity is defined by a CDAI >22 [19].
A patient with moderate disease activity was identified
when the patient’s CDAI score changed from low disease
activity or remission to moderate disease activity. This
patient was then followed for any disease activity transi-
tions from that initial transition to a moderate state.
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Model disease activity states
Model
RA patients are considered to transition over time
among disease states defined by CDAI. While the disease
activity score is a continuous scale, the discrete states
are used for clinical guidance. Markov models provide a
convenient probability model for examining discrete
states and estimating the likelihood of patient transitions
among states. They can be estimated with simple models
based on a patient’s current state or more complex
models that account for patient transition history. The
models provide population-based estimates on transi-
tions and with the inclusion of patient covariates can
and would provide clinically relevant information.
Figure 1 illustrates a model using three states (remission/
low, moderate, and high) where transition probabilities (πij)
are defined as the probability of moving from one state to
another (i ≠ j), or remaining in the same state (i = j). For
example, πLM represents the probability of transitioning
from low disease to moderate disease while πLL represents
the probability of remaining in low disease state.
A full description of the Markov chain methodology is
provided in the Additional file 1.
Model fit and variable time intervals
Within the model framework the impact of a range of
covariates on patient movement among disease states can
be examined. With clinical registry data collected at a
patient’s usual clinical visit, the time between visits will vary
and it is important to first assess the potential confounding
of the time between visits on transition probabilities to
understand adjustments to the model that may be needed
for visit interval variation.
The 3-state model was fit using multinomial logistic
regression models with a robust variance estimator to
account for remaining intragroup (within patient) correl-
ation across visits. The 3-state model was also fit using a
multi-state model to describe how an individual moves
between states and fitting the transition probability matrix
over an interval of 6 months. Mean months to switching
states were estimated based on the probabilities of the
next move of the process [20]. The current disease activity
state was modeled as a function of the prior state and the
time between visits divided into quintiles. The interaction
of prior state and time between visits was included in the
model to examine the impact of time interval on
estimated transition probabilities. In addition, predicted
transition probabilities from the multinomial model were
estimated for the full population and for those patients
with all visit intervals between 3 and 9 months (regular-
visit sub-cohort) to examine the impact of variability of
visits on the model estimates.
Additional fits used the 2-state model to illustrate the
model fitting and interpretation. A logistic regression
model for the current disease state was fitted with a robust
variance estimator. The interaction of select covariates
and the prior state were used in the model. We examined
three factors (in addition to controlling for visit interval):
year (to examine trends over time based on evolving treat-
ment guidelines and availability of new treatments),
Fig. 1 Transition probabilities for the 3-state model of disease severity. π probability, LL transition from low to low activity, LS transition from low
to severe activity, LM transition from low to moderate activity, MM transition from moderate to moderate activity, ML transition from moderate to
low activity, MS transition from moderate to severe activity, SM transition from severe to moderate activity, SL transition from severe to low
activity, SS transition from severe to severe activity
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disease duration (stability of disease with duration), and
age (impact of aging on disease variability). Covariates
were measured at each time point (visit). All models were
adjusted for the length of time between visits (3–4, 4–5,
5–6, 6–7, 7–8, 8–9 months). Covariates examined were
chronological year (2001–2004, 2005–2006, 2007–2008,
2009–2010, 2011–2012, 2013–2014), duration of disease
(0–3, 3–10, >10 years) and age (<50, 50–64, ≥65 years).
Results
Patient demographic and clinical characteristics are shown
in Table 1. The regular-visit sub-cohort was similar to the
full population except for slightly lower disease activity,
functionality, and duration of RA. The interquartile range
(IQR) for visit intervals in the full population was 3.5–
6.2 months (mean 5.4 months; standard deviation (SD)
3.1). In the regular-visit sub-cohort the IQR was 4.0–
6.2 months (mean 5.3 months; SD 1.5). There were 8304
patients among the full population that were in moderate
disease activity at their first visit as defined in “Methods.”
Table 2 shows the estimated transition probabilities
using the full population from the 3-state model based on
the multinomial model. Probabilities using the regular-
visit cohort were similar, with differences in the estimates
ranging from 0.0 to 0.05 for the 3-state model. Table 2
also presents the estimated transition probabilities from
the 3-state model considering a multi-state model over an
interval of 6 months; these estimates are similar to the ori-
ginal 3-state model. Among patients in moderate disease
activity, mean time to another state was 4.25 months
(standard error (SE) 0.04 months), meaning that the mean
time that a patient remained in moderate disease activity
was 4.25 months. This estimate was greatly increased
among patients in low disease activity (mean 19.38 (SE
0.15) months) and similar among patients in severe dis-
ease activity (mean 5.30 (SE 0.06) months).
We further assessed the impact of the length of visit inter-
vals on transition probabilities using the interaction of visit
interval and prior state in the regular-visit sub-cohort.
Additional file 1: Tables S1 and S2 show the estimated odds
ratios (ORs) of the estimated model with interaction terms
and the estimated increased (or decreased) risk of moderate/
severe disease if the prior state was low or moderate/severe.
A large OR (12.4) suggested an increased risk of the current
state being moderate/severe if the prior state was moderate/
severe vs low for the reference visit interval of 3–4 months.
The estimated ORs for the risk of transitioning from
low disease to moderate disease were all >1, indicating
higher odds of transitioning from a prior state of low to
a current state of moderate/severe if the visit interval
was longer but not all were significant. The estimated
ORs for the risk of transitioning from moderate disease
to moderate disease were all < 1, indicating lower odds
of remaining in moderate disease with longer intervals.
Again, the estimated ORs were close to 1 and not all
statistically significant. The impact of the length of visit
intervals was not large, but suggested that models
should be adjusted for this potential confounder.
To illustrate how the model can examine covariate asso-
ciations with transition probabilities we examined three
Table 1 Patient demographic and clinical characteristics
Full population (excluding those with regular visits)
(n = 20,041)
Regular visits sub-cohort
(n = 9812)
Age, mean years (SD) 57.9 (13.4) 59.3 (13.5)
Sex, n female (%) 15,193 (76.3) 7360 (75.8)
Duration of RA, mean years (SD) 9.1 (9.7) 8.7 (9.7)
Disabled, n (%) 2439 (12.3) 1072 (11.1)
Patient paina, mean score (SD) 34.6 (27.7) 33.6 (27.8)
TJC28, mean n (SD) 4.6 (6.2) 4.1 (5.8)
SJC28, mean n (SD) 4.5 (5.6) 3.6 (5.0)
PtGA, mean score (SD) 32.0 (26.7) 30.9 (26.6)
PGA, mean score (SD) 25.7 (21.9) 23.5 (21.5)
CDAI, mean score (SD) 14.8 (13.3) 13.0 (12.6)
CDAI category, n (%)
Low (score >2.8 to ≤10) 9435 (47.1) 5269 (53.7)
Moderate (score >10 to ≤22) 5674 (28.3) 2634 (26.8)
Severe (score >22) 4929 (24.6) 1909 (19.5)
History of biologic DMARD use, n (%) 9411 (47.0) 4485 (45.7)
SD standard deviation, RA rheumatoid arthritis, TJC28 tender joint count based on 28 joints, SJC28 swollen joint count based on 28 joints, PtGA patient global
assessment, PGA physician global assessment, CDAI Clinical Disease Activity Index, DMARD disease-modifying antirheumatic drug
aPatient pain was rated on a visual analog scale of 0–100
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factors: year, disease duration, and age. Separate models
adjusted only for visit intervals (not shown) estimated a
significant interaction of the prior disease state and year
and disease duration but no significant interaction with
age. Table 3 shows the results from the multivariable
logistic model using all four factors.
Effects over time were seen in the probability of transi-
tioning from a low disease state to moderate/severe dis-
ease with ORs <1 for 2007 onward, indicating a lower
likelihood of moving to moderate/severe disease from a
low disease state. There was little to no impact on the
transition probabilities of remaining in moderate disease
with ORs close to 1. Longer disease duration had lower
odds for transition from low to moderate/severe disease
but higher odds for remaining in moderate/severe dis-
ease. Age effects were similar regardless of prior disease
state (interaction not significant) so were added to the
model only as a main effect. ORs were close to 1, with
the OR for age 50–64 years estimated at 1.2, indicating
this age group was at a slightly higher risk of ending in
moderate/severe disease (whether transitioning from low
disease or remaining in moderate/severe disease).
Discussion
The severity of RA symptoms is currently unpredictable
with clinical tools or with laboratory or imaging biomarkers,
making management of this chronic disease a challenge for
both patients and physicians [21]. Only a fraction of patients
will reach constant and longstanding remission while on
one or more therapies. More frequently, disease activity fluc-
tuates over time despite therapy, due to a variety of reasons,
such as development of resistance to medications, increases
in the activity of the RA-related autoimmune process, or
other factors that may interfere with medication effective-
ness. Several studies of separate populations have shown
that a considerable fraction of patients with RA have moder-
ate or high disease activity [8–10]. In our study of a subset
of biologic-agent-naïve patients in the Corrona database
with disease duration >1 year, rates of low, moderate, and
Table 2 Estimated transition probabilities
Prior
state
Current state
Low Moderate Severe
3-State model
Full population Low 0.82 0.15 0.03
Moderate 0.47 0.35 0.18
Severe 0.13 0.39 0.48
Regular-visit sub-cohort Low 0.84 0.13 0.03
Moderate 0.52 0.33 0.15
Severe 0.16 0.41 0.43
3-State model assuming a 6-month interval
Full population Low 0.81 0.15 0.05
Moderate 0.46 0.37 0.17
Severe 0.26 0.33 0.41
Regular-visit sub-cohort Low 0.84 0.13 0.03
Moderate 0.48 0.38 0.14
Severe 0.28 0.34 0.38
Table 3 Covariate associations with transition probabilities
Covariate OR (95% CI)
Year (reference: 2001–2004)
Effect on transition from low to moderate/severe disease
2005–2006 0.865 (0.700 to 1.068)
2007–2008 0.593 (0.471 to 0.746)
2009–2010 0.583 (0.474 to 0.716)
2011–2012 0.615 (0.506 to 0.748)
2013–2014 0.605 (0.497 to 0.735)
Effect on transition from moderate/severe to moderate/severe disease
2005–2006 1.055 (0.853 to 1.304)
2007–2008 0.911 (0.733 to 1.133)
2009–2010 0.824 (0.679 to 0.999)
2011–2012 0.888 (0.740 to 1.066)
2013–2014 1.004 (0.837 to 1.205)
Duration of RA (reference: 0 to 3 years)
Effect on transition from low to moderate/severe disease
3 to 10 years 0.777 (0.698 to 0.865)
>10 years 0.840 (0.752 to 0.939)
Effect on transition from moderate/severe to moderate/severe disease
3 to 10 years 1.167 (1.045 to 1.303)
>10 years 1.379 (1.236 to 1.539)
Age (reference: <50 years)a
50 to 64 years 1.176 (1.082 to 1.279)
≥65 years 1.024 (0.939 to 1.117)
Visit interval (reference: 3 to < 4 months)
Effect on transition from low to moderate/severe disease
4 to <5 months 1.057 (0.940 to 1.187)
5 to <6 months 1.085 (0.961 to 1.226)
6 to <7 months 1.201 (1.057 to 1.364)
7 to <8 months 1.349 (1.160 to 1.568)
8 to 9 months 1.171 (0.977 to 1.403)
Effect on transition from moderate/severe to moderate/severe disease
4 to <5 months 0.931 (0.831 to 1.042)
5 to <6 months 0.801 (0.712 to 0.902)
6 to <7 months 0.779 (0.686 to 0.886)
7 to <8 months 0.799 (0.683 to 0.935)
8 to 9 months 0.866 (0.729 to 1.028)
CI confidence interval, RA rheumatoid arthritis
aNo interaction with prior state and age was noted so the effect was the same
for the transition from low to moderate/severe and from moderate/severe to
moderate/severe disease
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high disease activity were approximately 58%, 30%, and 12%,
respectively [22]. The Markov models used in these analyses
provide insight into patients with moderate disease and esti-
mated transitions among disease levels in the real world,
and provide a proof of concept of using these models to
understand covariates associated with transition probabilities
even when clinic visits are not at fixed intervals.
Markov models based on real-world data from patients
with RA were used in this study to estimate disease state
transition probabilities from clinical visit to clinical visit.
We analyzed data from all RA patients in the Corrona data-
base and the subset of patients with relatively regular visits
with a range of intervals from 3 to 9 months. The transition
probabilities remained stable even with longer times be-
tween visits, demonstrating the robustness of this method-
ology when applied to data from real-world practice.
Our results showed that for a patient in low disease
activity, the probability of moving to moderate disease
was 15% and to severe disease was 3% over an interval
of 6 months. Thus over a 6-month period a patient has a
20% chance of moving out of low disease activity. In
patients with moderate disease, while there was a 47%
probability of moving to low disease, there was still 53%
probability of remaining in moderate disease or even
moving to severe disease. Patients with severe disease had
48% probability of remaining in the severe state, 39%
probability of moving to moderate disease, and only 13%
probability of achieving low disease activity. Patients in
moderate disease activity remained in that state for an
average of only 4 months, whereas patients in low disease
activity remain there for an average of approximately
19 months. This illustrates the need to better understand
the treatment of patients in moderate disease activity so
that their disease can be managed so as to increase the
likelihood that a patient will proceed to low rather than
high disease activity. A renewed emphasis on the treat-to-
target strategy and its timing specifically in patients with
moderate disease might be considered.
Modeling approaches like the one used in this study may
help us better understand the natural history of the disease
in the era of biologic and targeted synthetic medications.
Such approaches may be used to evaluate the effectiveness
of therapies on a population level, and perhaps identify
areas for improvement in therapy and the need for more
aggressive treatment. These models indicate an unmet need
for an expanded array of treatment options for patients
with moderate or severe disease. Notably, these models and
observations could have only been obtained from very large
data sets, such as the Corrona registry.
The models were able to illustrate changing trends in
disease state movement across the years and as duration
of disease increased in patients. The lower odds in the
later years for transitioning from low to moderate dis-
ease illustrate how treatment strategies have developed
over time that have enabled patients to remain in low
disease activity. However, the impact has not extended
to moving at least some patients from moderate to low
disease as illustrated by the similar time to transition
over the years, another indication of unmet need in the
RA population. Longer duration of disease showed lower
odds of transitioning from low to moderate disease,
which may be an indication of more disease fluctuations
at disease onset as best treatments are determined. How-
ever, there were greater odds of remaining in moderate
disease with longer duration, which may also indicate
stability of RA severity in patients with long-standing
disease and more difficulty in changing the disease state.
Prior use of Markov models in RA [13–16] have con-
centrated on health economic models. The proposed
models reported here were used as a tool to assess factors
that impact the transition probabilities, which would assist
in understanding population trends and eventually indi-
vidual modifiable factors. Markov models assume that a
patient is always in one of a finite number of discrete
health states, called Markov states. All events are repre-
sented as transitions from one state to another. Disease
activity is a continuous measure and the discrete Markov
states are therefore artifacts that are used to summarize
changes in disease activity. However, the spectrum of RA
disease severity fits within a clinical paradigm related to
treatment changes and “treat-to-target” goals, and pro-
vides a simplified model of patient disease fluctuations.
Limitations to the study include restriction to the
single index of CDAI (potentially inflated by chronic
damage in patients with longstanding disease) and the
limited covariates used in proof-of-concept work.
Additional disease measures and states and additional
covariates can be examined in future work.
Conclusion
In summary, this work provides a proof of concept of the
Markov model for assessing associations with disease state
transitions in patients with RA and insights into how treat-
ment trends over time have impacted these transition times.
Even with variable visit intervals the model provided robust
estimates, and further studies to examine effects of other var-
iables on changes in the severity of RA disease activity are
warranted. In addition, our results indicate that while the
mean time in moderate disease is short, indicating effective
treatment in many patients, there is still a substantial propor-
tion that remain in moderate disease after 6 months (or
worse, have an increase in severity to severe disease), indicat-
ing an unmet need in the treatment of patients with RA. Fu-
ture research should aim at determining specific modifiable
covariates that can impact disease transitions and allow de-
velopment of algorithms that could possibly be applied to in-
dividual patients to predict fluctuations of disease activity and
assist in decisions regarding the aggressiveness of therapy.
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Additional file
Additional file 1: Supplemental methods - Markov chain. Table S1.
Model with visit interval interaction. Table S2. Impact of visit interval on
transition probabilities. (PDF 25 kb)
Abbreviations
bDMARD: Biologic Disease-modifying antirheumatic drug; CDAI: Clinical
Disease Activity Index; DMARD: Disease-modifying antirheumatic drug;
OR: Odds ratio; RA: Rheumatoid arthritis; SD: Standard deviation; SE: Standard error
Acknowledgements
Dikran Toroser (Amgen Inc.) and Julia R. Gage (on behalf of Amgen Inc.)
assisted with editing the manuscript.
Funding
This study was sponsored by Corrona, LLC. The Corrona RA registry has been
supported through contracted subscriptions in the last two years by AbbVie Inc.,
Amgen Inc., Astra Zeneca, Bristol-Myers Squibb Co., Crescendo Pharmaceuticals
Corp., Genentech Inc., Horizon Pharma USA, Janssen Pharmaceuticals, Inc., Eli Lilly
and Co., Novartis International AG, Pfizer Inc., and UCB, Inc. Financial support for
this study was provided by Immunex, a wholly owned subsidiary of Amgen Inc.
and by Wyeth, which was acquired by Pfizer in October 2009.
Availability of data and materials
The data that support the findings of this study are available through Corrona,
LLC, but restrictions apply to the availability of these data, which were used under
a subscription agreement for the current study, and so are not publicly available.
Authors’ contributions
GWR contributed to the conception and design of the study, acquisition of data,
analysis of the data, interpretation of the results, and drafting and critically revising the
manuscript. DHC contributed to the conception and design of the study, analysis of
data, interpretation of results, and drafting and critically revising the manuscript. ASK
contributed to the conception and design of the study, analysis of data,
interpretation of results, and drafting and critically revising the manuscript. KCS
contributed to the conception and design of the study, analysis of data,
interpretation of results, and critically revising the manuscript. DAP contributed to the
interpretation of the data and critically revising the manuscript. HJL contributed to
the analysis of the data, interpretation of the results, and critically revising the
manuscript. JMK contributed to acquisition of data, analysis of data, interpretation of
the results, and drafting and critically revising the manuscript. SK contributed to the
interpretation of the results and critically revising the manuscript. All authors
approved the final submitted draft of the manuscript.
Competing interests
GWR is an employee and shareholder of Corrona, LLC, and holds an appointment at
University of Massachusetts. DHC is an employee and shareholder of Amgen Inc. ASK
is an employee and shareholder of Pfizer Inc. SK is a former employee and
shareholder of Pfizer Inc. KCS and HJL are employees of Corrona, LLC. DAP is an
employee of Corrona, LLC and instructor for Novartis. JMK serves on advisory boards
for AbbVie, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Eli Lilly and Company,
and Pfizer, Inc.; serves on the board of directors for Corrona, LLC; is an investigator for
AbbVie, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Eli Lilly and Company,
and Pfizer, Inc.; is on the speaker’s bureau for Amgen Inc., and is a shareholder of
Corrona, LLC. No non-financial conflicts of interest exist for any of the authors.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Due to the non-interventional, observational study design, use of a limited
dataset (i.e., contains no direct identifiers) is exempt from institutional review
board (IRB) and ethics committee (EC) review. The Corrona RA US protocol
was reviewed and approved by a central IRB, New England Independent
Review Board (NEIRB). For academic investigative sites that did not receive a
waiver to use the central IRB, full board approval was obtained from the
respective governing IRBs and documentation of approval was submitted to
the Sponsor prior to initiating any study procedures. All registry subjects
were required to provide written informed consent prior to participating.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1University of Massachusetts Medical School, 55 Lake Ave North, Worcester,
MA 01605, USA. 2Amgen Inc., Thousand Oaks, CA, USA. 3Pfizer Inc.,
Collegeville, PA, USA. 4Corrona LLC, Southborough, MA, USA. 5Columbia
University College of Physicians and Surgeons, New York, NY, USA. 6Albany
Medical College and The Center for Rheumatology, Albany, NY, USA.
Received: 19 August 2016 Accepted: 7 April 2017
References
1. Choy E. Understanding the dynamics: pathways involved in the pathogenesis
of rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v3–11.
2. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis.
Rheumatology (Oxford). 2012;51 Suppl 6:vi28–36.
3. Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot
E, McNaughton C, Osani M, Shmerling RH, et al. 2015 American College of
Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis
Rheumatol. 2016;68(1):1–26.
4. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser
H, van de Laar MA, van Riel PL. Long-term effectiveness and safety of TNF-
blocking agents in daily clinical practice: results from the Dutch Rheumatoid
Arthritis Monitoring register. Rheumatology (Oxford). 2011;50(1):196–203.
5. Uhlig T, Lie E, Norvang V, Lexberg AS, Rodevand E, Kroll F, Kalstad S, Olsen
IC, Kvien TK. Achievement of remission and low disease activity definitions
in patients with rheumatoid arthritis in clinical practice: Results from the
NOR-DMARD Study. J Rheumatol. 2016;43(4):716–23.
6. Conigliaro P, Chimenti MS, Triggianese P, Ballanti E, Sunzini F, Duca I,
Perricone R. Remission and low disease activity in a cohort of real-life
patients with rheumatoid arthritis treated with first-line antitumour necrosis
factor. J Int Med Res. 2016;44(1 suppl):90–4.
7. Einarsson JT, Geborek P, Saxne T, Kristensen LE, Kapetanovic MC. Sustained
remission improves physical function in patients with established rheumatoid
arthritis, and should be a treatment goal: a prospective observational cohort
study from southern Sweden. J Rheumatol. 2016;43(6):1017–23.
8. Carpenter L, Nikiphorou E, Norton S, Jayakumar K, Dixey J, Young A. Patients
with moderate disease activity in the first 5 years of rheumatoid arthritis still
progress radiographically despite conventional disease modifying therapy
(abstract 2135). Arthritis Rheum. 2014;66(10 Suppl):S933–4.
9. Nikiphorou E, Norton S, Young A, Carpenter L, Dixey J, Walsh DA, Kiely P,
Davies P, Hill L, Gough A, et al. Association between rheumatoid arthritis
disease activity, progression of functional limitation and long-term risk of
orthopaedic surgery: combined analysis of two prospective cohorts
supports EULAR treat to target DAS thresholds. Ann Rheum Dis. 2016;75(12):
2080–6.
10. Nikiphorou E, Carpenter L, Norton S, Kiely P, Dixey J, Young A. Different levels
of moderate disease in rheumatoid arthritis (RA) are associated with varying
risk for joint destruction and failure. Time to update DAS cut-offs for biologic
DMARD use? (abstract OP0179). Ann Rheum Dis. 2015;74 Suppl 2:139.
11. Pappas DA, Kent JD, Greenberg JD, Mason MA, Kremer JM, Holt RJ. Delays
in initiation of disease-modifying therapy in rheumatoid arthritis patients:
Data from a US-based registry. Rheumatol Ther. 2015;2(2):153–64.
12. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR,
Hochberg MC, Tsao P, Greenberg JD. Disease activity in rheumatoid arthritis
and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449–55.
13. Scholz S, Mittendorf R. Modeling rheumatoid arthritis using different techniques -
a review of model construction and results. Health Econ Rev. 2014;4:18.
14. Beresniak A, Dupont DM, Becker JC, Merkesdal S. Interest of modelling in
rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S96–101.
15. Kobelt G, Lindgren P, Young A. Modelling the costs and effects of
leflunomide in rheumatoid arthritis. Eur J Health Econ. 2002;3(3):180–7.
16. Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. Modelling the
effect of function and disease activity on costs and quality of life in
rheumatoid arthritis. Rheumatology (Oxford). 2005;44(9):1169–75.
17. Kremer J. The CORRONA database. Ann Rheum Dis. 2005;64 Suppl 4:iv37–41.
18. Greenberg JD, Bingham 3rd CO, Abramson SB, Reed G, Sebaldt RJ, Kremer J.
Effect of cardiovascular comorbidities and concomitant aspirin use on
Reed et al. Arthritis Research & Therapy  (2017) 19:81 Page 7 of 8
selection of cyclooxygenase inhibitor among rheumatologists. Arthritis
Rheum. 2005;53(1):12–7.
19. Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment
response in rheumatoid arthritis based on the simplified and the clinical
disease activity index. Ann Rheum Dis. 2012;71(7):1190–6.
20. Jackson C. Multi-state models for panel data: The msm package for R. J
Statistical Software. 2011;38(8):1–28.
21. Flurey CA, Morris M, Richards P, Hughes R, Hewlett S. It’s like a juggling act:
rheumatoid arthritis patient perspectives on daily life and flare while on
current treatment regimes. Rheumatology (Oxford). 2014;53(4):696–703.
22. Harrold LR, Harrington JT, Curtis JR, Furst DE, Bentley MJ, Shan Y, Reed G,
Kremer J, Greenberg JD. Prescribing practices in a US cohort of rheumatoid
arthritis patients before and after publication of the American College of
Rheumatology treatment recommendations. Arthritis Rheum. 2012;64(3):630–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Reed et al. Arthritis Research & Therapy  (2017) 19:81 Page 8 of 8
